Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats.
Ginsenoside Rb1 reduces fatty liver by activating AMP-activated protein kinase in obese rats.
复制标题
DOI：
10.1194/jlr.m035907
复制
发表时间：
2013-05-01
影响因子：
6.5
通讯作者：
Liu, Min
中科院分区：
文献类型：
--
作者：
Shen, Ling;Xiong, Ye;Liu, Min
人参皂苷Rb 1（Ginsenoside Rb 1，Rb 1）是从人参中提取的天然化合物，对高脂饮食诱导的肥胖大鼠具有抗肥胖和改善胰岛素敏感性的作用。本研究的目的是评估Rb 1对HFD诱导的肥胖大鼠脂肪肝的保护作用，并阐明其机制。慢性腹腔给药后，Rb 1（10 mg/kg）显着改善HFD诱导的肥胖大鼠的肝脏脂肪堆积，表现为降低肝脏重量，肝甘油三酯含量，肝切片的苏木精和伊红和油红O染色的组织学评价。使用原代培养的大鼠肝细胞，我们发现，脂肪酸氧化的速率和肉毒碱棕榈酰转移酶1（CPT 1），脂肪酸β-氧化的关键酶的活性，显着升高Rb 1处理的肝细胞相比，那些车辆处理的细胞。HPLC分析显示，Rb 1增加细胞AMP/ATP比，这与肝AMP活化蛋白激酶（AMPK）和磷酸化乙酰辅酶A羧化酶的激活升高有关。与AMPK的激活一致，通过定量PCR评估，Rb 1刺激编码脂肪酸氧化酶和蛋白质的基因的表达，并抑制编码在脂肪生成中发挥作用的酶或蛋白质的基因的表达。我们的结论是，Rb 1有一个强大的能力，以减少肝脏脂肪的积累，并可能是有用的脂肪肝疾病的治疗剂。
Ginsenoside Rb1 (Rb1), a natural compound extracted from ginseng, exerts anti-obesity activity and improves insulin sensitivity in high-fat diet (HFD)-induced obese rats. The objective of the current study was to evaluate the protective effect of Rb1 on fatty liver in HFD-induced obese rats and to elucidate underlying mechanisms. After chronic intraperitoneal administration, Rb1 (10 mg/kg) significantly ameliorated hepatic fat accumulation in HFD-induced obese rats, as demonstrated by reduced liver weight, hepatic triglyceride content, and histological evaluation of liver sections by hematoxylin and eosin and Oil Red O staining. Using primary cultured rat hepatic cells, we found that the rate of fatty acid oxidation and the activity of carnitine palmitoyltransferase 1 (CPT1), a key enzyme in fatty acid beta-oxidation, were significantly elevated in Rb1-treated hepatocytes compared with those of vehicle-treated cells. HPLC analysis revealed that Rb1 increased the cellular AMP/ATP ratio, which is associated with elevated activation of hepatic AMP-activated protein kinase (AMPK) and phosphorylated acetyl-CoA carboxylase. Consistent with the activation of AMPK, Rb1 stimulated the expression of genes encoding fatty acid oxidative enzymes and proteins, and suppressed the expression of genes encoding enzymes or proteins that function in lipogenesis, assessed by quantitative PCR. We conclude that Rb1 has a potent ability to reduce hepatic fat accumulation and might be useful as a therapeutic agent for fatty liver disorder.